drugset / Trial / NCT00838630

Cilostazol 100 mg Tablet Formulations Under Fasting Conditions

NCT00838630

Phase 1 Completed 36 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this randomized, single-dose, two-way evaluation is to compare the bioequivalence of a test cilostazol formulation to an equivalent oral dose of the commercially available cilostazol in a test population of 36 adult subjects under fasting conditions.

Timeline

Start
2003-11
Primary completion
2003-11
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilostazol Small molecule 100 mg Oral

Indications

No indication recorded.